News briefing: Biogen settles False Claims Act dispute for $22M; Lantern Pharma, Johns Hopkins join forces to advance glioblastoma therapy
Massachusetts-based Biogen this week agreed to an expensive settlement with the Department of Justice over a whistleblower’s claims it violated …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
